Pfizer pats itself on the back for tax reform lobbying, do-gooder investments

On Pfizer’s fourth-quarter conference call, Morgan Stanley analyst David Risinger congratulated company executives on their “efforts to educate Washington having finally paid off.” And the way CEO Ian Read sees it, those congratulations are well deserved.Original Article